Calithera Biosciences, Inc. (CALA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

0.7457

-0.0523

(-6.55%)

As of 12:03PM EST. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	0.7980
Open	0.7900
Bid	0.7464 x 1000
Ask	0.7522 x 1400
Day's Range	0.7411 - 0.7973
52 Week Range	0.7411 - 6.1850
Volume	425,422
Avg. Volume	1,694,591

Market Cap	55.872M
Beta (5Y Monthly)	1.55
PE Ratio (TTM)	N/A
EPS (TTM)	-0.9410
Earnings Date	Nov 09, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	1.83

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CALA

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Calithera Biosciences, Inc.
Analyst Report: Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Rating
Fair Value
Economic Moat
yesterdayMorningstar

All

News

Press Releases

Research Reports

Zacks
Do Options Traders Know Something About Calithera Biosciences (CALA) Stock We Don't?
Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, investor! We’re getting right into the thick of it today with a look at the biggest pre-market stock movers for Thursday! Source: ventdusud / Shutterstock.com Earnings reports, IPOs, acquisition news, and more have stocks moving during this morning’s pre-market trading. Let’s dive into those pre-market stock movers below!InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-Market Stock Movers: 10 Top Gainers Sono Group (NASDAQ:SEV) stock is soaring more than 27% after
GlobeNewswire
Calithera to Present at the 2021 Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the 2021 Jefferies London Healthcare Conference. The presentation will be available for on-demand viewing starting Thursday, November 18 at 3:00 a.m. Eastern Time, and can be accessed through the Investors